Skip to main content
Clinical Trials/NCT04808830
NCT04808830
Completed
Not Applicable

Prevalence of Musculoskeletal Pain and Its Impact on Quality of Life and Functional Exercise Capacity in Patients With Pulmonary Arterial Hypertension

Izmir Bakircay University1 site in 1 country61 target enrollmentMarch 25, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pulmonary Arterial Hypertension
Sponsor
Izmir Bakircay University
Enrollment
61
Locations
1
Primary Endpoint
The Nordic Musculoskeletal Questionnaire
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Prevalence of musculoskeletal pain and its impact of quality of life and functional exercise capacity will be evaluated in patients with pulmonary arterial hypertension.

Detailed Description

Although main symptoms of pulmonary arterial hypertension (PAH) include shortness of breath and exercise intolerance, patients may also experience symptoms related to musculoskeletal system such as muscle fatigue or pain. Due to insufficient cardiac output and chronic arterial hypoxemia, oxygen cannot be delivered to skeletal muscles sufficiently, especially during exertion. In addition, inflammation, which is thought to play an important role in pulmonary vascular remodeling and disease pathophysiology in these patients, affects skeletal muscles as well. Increased sympathetic tone in PAH restricts the perfusion of skeletal muscle by increasing peripheral vascular resistance. With the addition of physical inactivity to all these factors, skeletal muscle metabolism is further impaired. Furthermore, drugs used for the treatment of PAH may induce musculoskeletal pain as a side effect. Musculoskeletal pain is one of the most important factors impairing individual's quality of life, regardless of whether there is an underlying disease. Our aim in this study is to evaluate pain prevalence in the musculoskeletal system over 9 body regions, to compare the pain prevalence of patients using different types of PAH drugs and to examine impact of musculoskeletal pain on quality of life and functional capacity in patients with PAH.

Registry
clinicaltrials.gov
Start Date
March 25, 2021
End Date
June 15, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Izmir Bakircay University
Responsible Party
Principal Investigator
Principal Investigator

Melih Zeren

Assist. Prof. Dr.

Izmir Bakircay University

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of pulmonary arterial hypertension

Exclusion Criteria

  • Diagnosis of heart failure or any chronic respiratory disease
  • Recent coronary bypass surgery
  • Recent acute myocardial infarction
  • Having a pacemaker
  • Having any orthopedic or neurologic diseases which may impede walking or exercising

Outcomes

Primary Outcomes

The Nordic Musculoskeletal Questionnaire

Time Frame: At baseline

The Nordic Musculoskeletal Questionnaire will be used to evaluate musculoskeletal pain prevalence.

Secondary Outcomes

  • The EmPHasis-10 questionnaire(At baseline)
  • The Minnesota Living with Heart Failure Questionnaire(At baseline)
  • 6-min walk distance(At baseline)
  • International Physical Activity Questionnaire - Short Form(At baseline.)

Study Sites (1)

Loading locations...

Similar Trials